posted
eFoodSafety.com Inc. Reports Bird Flu Outbreaks in Thailand - One Death Confirmed Tuesday August 22, 10:05 am ET
SCOTTSDALE, Ariz.--(BUSINESS WIRE)--Aug. 22, 2006--Patricia Gruden, president/CEO of eFoodSafety.com Inc. (OTCBB: EFSF - News), reported today that additional outbreaks of the Bird Flu have occurred in humans in Thailand's northern Uttaradit province, with one confirmed death in the northern province of Phichit. according to Public Health officials, two men had contact with an unidentified species of wild bird, where they shot, cooked, and had eaten the bird, but afterwards both fell ill and were admitted to the Uttaradit Provincial Hospital.
The death of a 17-year-old youth from Phichit has been confirmed to be from infection of the deadly H5N1 Bird Flu virus. He suffered from an acute lung infection and flu-like symptoms after he had buried 20 fowls that had died of unknown causes in his village.
The announcement of his passing came a day after the Agriculture and Cooperatives Ministry confirmed a fresh outbreak of the H5N1 Bird Flu strain in Phichit's Bang Mun Nak district.
"Our focus of testing in this East Asian region is proving to be prudent. As continued outbreaks occur within this locality, it is our desire for Citroxin to gain recognition as a solution to this potential pandemic," stated Gruden.
About eFoodSafety.com Inc.
eFoodSafety.com Inc. is dedicated to improving health conditions around the world through its innovative technologies. The company's Knock-Out Technologies, Ltd. subsidiary has developed an environmentally safe sporicidal product formulated entirely of food-grade components that eradicates anthrax and a germicidal product, Citroxin (formerly named Big Six Plus) - EPA Reg. No. 82723-1 that kills six major bacteria: E-coli, Listeria, Pseudomonas, Salmonella, Staphylococcus, and Streptococcus, Avian Influenza, and Black Mold. The sporicidal product has completed its final efficacy laboratory study requisite for EPA registration. In the study, it eradicated both Clostridium Sporogenes and Bacillus Subtilis with 100% efficacy on both hard and porous surfaces. The company's MedElite Inc. subsidiary distributes clinically proven products to physicians who then prescribe the products for their patients. It is the exclusive U.S. and worldwide distributor of the Talsyn(TM)-CI/bid Scar Cream that has been clinically proven to facilitate and improve the appearance, redness and strength of scars (www.talsyn.com). The company is also is a distributor for Cinnergen(TM), a non-prescription liquid whole food nutritional supplement that promotes healthy glucose metabolism (www.cinnergen.com), and Trimmendous(TM), a weight loss formula focusing on the body's 24-hour metabolic processes. The company has recently entered into a joint venture agreement with CK41 Direct Inc. to launch an anti-acne skin care system, with a branded name and celebrity spokesperson to-be-announced in the near future.
Statements contained in this release that are not strictly historical are "forward-looking" statements within the meaning of Section 27A of the Securities Act of 1933 as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. The forward-looking statements are made based on information available as of the date hereof, and the company assumes no obligation to update such forward-looking statements. Editors and investors are cautioned that such forward-looking statements involve risks and uncertainties and the company's actual results may differ from these forward-looking statements. Such risks and uncertainties include but are not limited to demand for the company's products and services, our ability to continue to develop markets, general economic conditions, our ability to secure additional financing for the company and other factors that may be more fully described in reports to shareholders and periodic filings with the Securities and Exchange Commission.
UBBFriend: Email this page to someone!
Printer-friendly view of this topic
